Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IVA Prostate Cancer AJCC v8: early-phase trial registry
14 of 27 indexed Stage IVA Prostate Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 14 currently recruiting · #598 of 28,707 conditions by registered trial count
Stage IVA Prostate Cancer AJCC v8: 27 US clinical trials tracked, 14 recruiting.
Stage IVA Prostate Cancer AJCC v8 is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 14 of them currently open to new participants. 8 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 7 of these trials.
Enrollment posture brief
Registry condition stage-iva-prostate-cancer-ajcc-v8
OPEN 14 | RECR 52% | LATE 8 | EARLY 17 | RANK #598 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Aortic Stenosis (52% recruiting · 27 trials)
Stage IVA Prostate Cancer AJCC v8 lists 14 open slots (52% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IVA Prostate Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IVA Prostate Cancer AJCC v8 is recruiting above its size-band peers.
14 of 27 indexed trials (51.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IVA Prostate Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 7 of 27 trials (25.9%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Stage IVA Prostate Cancer AJCC v8 enrolment sits around 70 participants.
Median target enrolment is 70 among the 27 trials that report a genuine target (sentinel values excluded). 16 of those (59.3%) plan for fewer than 100 participants.
-
Stage IVA Prostate Cancer AJCC v8 research is mostly interventional.
27 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
NCT03678025
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NRG Oncology
NCT05946213
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
NCT04134260
Vitamin D for Prostate Endocrine Therapy
University of Rochester
NCT05838716
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
M.D. Anderson Cancer Center
NCT05054296
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
NCT04947254
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Jonsson Comprehensive Cancer Center
NCT04915508
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
Emory University
NCT06650579
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
NCT04734730
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
Jonsson Comprehensive Cancer Center
NCT04945642
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
Mayo Clinic
NCT06389786
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
University of Utah
NCT05168618
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Jonsson Comprehensive Cancer Center
NCT05398302
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
NCT05113537
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
NCT04513717
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
NCT03987386
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
Alliance for Clinical Trials in Oncology
NCT05241860
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT04388852
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology
NCT04455750
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal
NCT04471974
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT03821792
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Thomas Hope
NCT04716725
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
NCT03873805
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04050215
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03204812
Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring
NRG Oncology
NCT04037254
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 11 |
| Phase 3 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IVA Prostate Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IVA Prostate Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IVA Prostate Cancer AJCC v8 page
27 registered trials, 14 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 14 Stage IVA Prostate Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage IVA Prostate Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IVA Prostate Cancer AJCC v8 condition card totals 27 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.